Format

Send to

Choose Destination
MAbs. 2017 Jul;9(5):735-741. doi: 10.1080/19420862.2017.1325052. Epub 2017 May 5.

Antibodies targeting G protein-coupled receptors: Recent advances and therapeutic challenges.

Author information

1
a PRC, INRA, CNRS, Université François-Rabelais de Tours , Nouzilly , France.
2
b LE STUDIUM® Loire Valley Institute for Advanced Studies , Orléans , France.
3
c Biology Department , College of Science, United Arab Emirates University , Al Ain , United Arab Emirates.
4
d Heptares Therapeutics Ltd , BioPark, Welwyn Garden City, Hertfordshire , UK.
5
e Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire, Université Libre de Bruxelles , Brussels , Belgium.
6
f Welbio, Université Libre de Bruxelles , Brussels , Belgium.
7
g Institut de Génomique Fonctionnelle (IGF), Université de Montpellier, CNRS UMR5203 , Montpellier , France.
8
h INSERM U1091 , Montpellier , France.
9
i Amsterdam Institute for Molecules Medicines and Systems (AIMMS), Division of Medicinal Chemistry, Vrije Universiteit , Amsterdam , The Netherlands.
10
j Structural Biology Brussels, Vrije Universiteit Brussels , Brussels , Belgium.
11
k Structural Biology Research Center, Vlaams Instituut voor Biotechnologie , Brussels , Belgium.
12
l Université François-Rabelais de Tours, CNRS, UMR 7292 , Tours , France.
13
m Laboratoire d'Immunologie, CHRU de Tours , Tours , France.
14
n Antibody Discovery and Protein Engineering, MedImmune , Cambridge , UK.

Abstract

Le STUDIUM conference was held November 24-25, 2016 in Tours, France as a satellite workshop of the 5th meeting of the French GDR 3545 on "G Protein-Coupled Receptors (GPCRs) -From Physiology to Drugs," which was held in Tours during November 22-24, 2016. The conference gathered speakers from academia and industry considered to be world leaders in the molecular pharmacology and signaling of GPCRs, with a particular interest in the development of therapeutic GPCR antibodies (Abs). The main topics were new advances and challenges in the development of antibodies targeting GPCRs and their potential applications to the study of the structure and function of GPCRs, as well as their implication in physiology and pathophysiology. The conference included 2 sessions, with the first dedicated to the recent advances in methodological strategies used for GPCR immunization using thermo-stabilized and purified GPCRs, and the development of various formats of Abs such as monoclonal IgG, single-chain variable fragments and nanobodies (Nbs) by in vitro and in silico approaches. The second session focused on GPCR Nbs as a "hot" field of research on GPCRs. This session started with discussion of the pioneering Nbs developed against GPCRs and their application to structural studies, then transitioned to talks on original ex vivo and in vivo studies on GPCR-selective Nbs showing promising therapeutic applications of Nbs in important physiologic systems, such as the central nervous and the immune systems, as well as in cancer. The conference ended with the consensus that Abs and especially Nbs are opening a new era of research on GPCR structure, pharmacology and pathophysiology.

KEYWORDS:

Antibody; G protein; GPCR; biopharmaceuticals; nanobody; phage display; β-arrestin

PMID:
28475474
PMCID:
PMC5524162
DOI:
10.1080/19420862.2017.1325052
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center